Also known as: late-stage pancreatic cancer
Pancreatic cancer is a highly lethal malignancy, most commonly pancreatic ductal adenocarcinoma, often diagnosed late because early symptoms are nonspecific.
Science and Neurosoft partnered on brain-computer interface technology. Biocytogen licensed a fully human VHH antibody to Qilu Pharmaceutical; MassBio and SCbio selected 10 startups for Drive cohorts.
Senticell closed an oversubscribed seed round of nearly $7 million to advance its red blood cell-based liquid biopsy platform. The company is running two clinical studies at Penn Medicine enrolling about 300 patients to compare its RBC signal against plasma-based tests.
Forecasts show the obesity and diabetes drugs market expanding through 2035 on GLP-1 adoption, Europe's HIFU market reaching USD 65.57B by 2033, and AI precision medicine growing at a 31.3% CAGR.
Merck and Moderna's personalized mRNA cancer vaccine combined with Keytruda significantly reduced melanoma recurrence risk in a Phase 3 trial. The FDA has not yet approved the vaccine, with potential availability expected by early 2027.
ASTRO issued updated pancreatic cancer radiation therapy guidelines covering resectable, locally advanced, recurrent, metastatic and palliative disease. The revision replaces 2019 recommendations and supports IMRT, daily image guidance, and respiratory motion assessment.
Johnson & Johnson agreed to buy Firefly Bio for $1 billion to advance KRAS-targeted cancer therapies. The company also announced a $1 billion cell therapy manufacturing plant in Pennsylvania as part of a $55 billion US investment plan.
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
The FDA granted Fast Track designation to Oncolytics Biotech's pelareorep combined with a checkpoint inhibitor for advanced squamous cell carcinoma of the anal canal. The designation follows encouraging GOBLET study data and supports development in an estimated $1 billion market with no approved therapies.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07814859 |
Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07814326 |
Feasibility of the Loop Brush EUS-FNA for Characterization of Pancreatic Cysts: Pilot Clinical Investigation |
NOT_YET_RECRUITING | NA |
| NCT07814066 |
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07808164 |
ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort |
RECRUITING | |
| NCT07806058 |
An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07805954 |
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma |
RECRUITING | PHASE3 |
| NCT07802418 |
Molecularly Tailored Therapy in Advanced Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07799298 |
Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) |
NOT_YET_RECRUITING | NA |
| NCT07796997 |
GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07796906 |
Five-Element Music Therapy for Psychological Distress in Pancreatic Cancer Chemotherapy |
NOT_YET_RECRUITING | NA |
